Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Opioid Use Disorder (OUD)

MDMA for Opioid Use Disorder (OUD)

4 papers and 1 clinical trial exploring mdma as a treatment for opioid use disorder (oud).

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationAn estimated 2 million people in the United States have OUD.

Opioid Use Disorder (OUD)

Opioid Use Disorder (OUD) is a prevalent and serious public health issue that is increasingly being targeted for treatment with psychedelics, particularly ibogaine. Recent studies suggest that these compounds may alleviate withdrawal symptoms and reduce cravings, presenting a potential shift in therapeutic approaches to OUD.

Full Opioid Use Disorder (OUD) profile

Academic Research

4 papers
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Paywallindividual

A non-hallucinogenic psychedelic analogue with therapeutic potential

This paper describes an analogue to ibogaine (tabernanthalog) with similar therapeutic potential that is non-toxic, and non-psychedelic.

Published
December 9, 2020
Journal
Nature
Authors
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., Mccarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., Rabow, Z. T., Fiehn, O., Wulff, H., Mccorvy, J. D., Lein, P. J., Kokel, D., Ron, D., Peters, J., Zuo, Y., Olson, D. E.
Open Accessindividual

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

This cross-sectional survey study (n=444) analyzed self-reported cases of reduced substance abuse disorder after using psychedelics and found that that the number of responders who fulfilled the criteria for their disorder dropped by 59% thereafter. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in drug consumption, and most respondents claimed lasting improvements for over 1 year after using a psychedelic.

Published
January 22, 2020
Journal
Frontiers in Psychiatry
Authors
Garcia-Romeu, A., Davis, A. K., Griffiths, R. R., Johnson, M. W., Nichols, C. D.
Open Accessmeta

Making a medicine out of MDMA

This commentary (2015) examines how inappropriate, non-evidence-based, legislative restrictions of MDMA have failed to mitigate the harms of recreational ecstasy use but have effectively halted clinical research for therapeutic use. They urge the regulatory authorities to re-schedule MDMA and promote research for therapeutic uses within psychiatry.

Published
January 1, 2015
Journal
British Journal of Psychiatry
Authors
Sessa, B., Nutt, D. J.

Clinical Trials

1 trial
RecruitingPhase II

MDMA for Co-occurring PTSD and OUD After Childbirth

This open-label trial (n=15) will assess feasibility, safety and preliminary efficacy of MDMA-assisted therapy (three monthly MDMA sessions with preparatory and integrative therapy) for postpartum people with co-occurring PTSD and Opioid Use Disorder.

Started
March 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT05219175

Explore further

Search all MDMA papers Search all Opioid Use Disorder (OUD) trials Full MDMA profile Full Opioid Use Disorder (OUD) profile